论文部分内容阅读
目的探讨小细胞肺癌(SCLC)骨髓转移的临床特征、治疗方法、生存期及预后影响因素。方法回顾性分析20例SCLC骨髓转移病例的临床资料,应用SPSS17.0统计学软件进行数据分析,并绘制生存曲线。结果 20例SCLC患者初诊时诊断局限期9例,广泛期11例。全组患者贫血11例,占55%,血小板减少5例,占25%;广泛期中位生存期为7.1个月,局限期中位生存期11.6个月。治疗均采用含足叶乙甙的化疗方案,局限期联合放疗的患者预后较好。结论化疗可延长小细胞肺癌骨髓转移患者生存期,局限期联合放疗的患者预后较好,分期、红细胞(PLT)减少为独立的预后影响因素。
Objective To investigate the clinical characteristics, treatment, survival and prognostic factors of bone marrow metastases from small cell lung cancer (SCLC). Methods The clinical data of 20 patients with bone marrow metastasis from SCLC were retrospectively analyzed. The data were analyzed by SPSS17.0 statistical software and the survival curves were drawn. Results The diagnosis of 20 cases of SCLC patients first diagnosed in 9 cases, a wide range of 11 cases. All patients in 11 cases of anemia, accounting for 55%, thrombocytopenia in 5 cases, accounting for 25%; extensive median survival was 7.1 months, the median survival time was 11.6 months. Treatment with etoposide containing chemotherapy regimens, combined with local radiotherapy in patients with better prognosis. Conclusion Chemotherapy can prolong the survival of patients with bone marrow metastases from small cell lung cancer. The patients with combined therapy and local radiotherapy have a better prognosis, and the reduction of erythrocytes (PLT) is an independent prognostic factor.